Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Tiragolumab × 30 days × Clear all

Phase

Status

Recruiting 4 Completed 2 Active not recruiting 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

Prednisone 3 Vincristine 2 Lenalidomide 2 Doxorubicin 2 Cyclophosphamide 2 tislelizumab 1 tazemetostat 1 tafasitamab 1 semaglutide 1 ribociclib 1 pembrolizumab 1 niraparib 1 monalizumab 1 fludarabine 1 etoposide phosphate 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 daratumumab 1 carfilzomib 1 auricularum 1 atezolizumab 1 Tiragolumab 1 Surveys and Questionnaires 1 Specimen Handling 1 Rituximab 1 Radiotherapy, Intensity-Modulated 1 Quality Assurance, Health Care 1 Prednisolone 1 Physical Therapy Modalities 1 Patient Education as Topic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06713798 2026-03-23

INDIGO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡